Weight loss drugs up abdominal paralysis risk: Study, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

The study, results of which has been published only in abstract form, found people who took Wegovy and Ozempic, also referred to as GLP-1 agonist drugs, were 30% more at risk of developing abdominal paralysis compared to those who did not. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), also known as GLP-1 agonists, are a class of medications used to treat Type 2 diabetes and obesity., The study, results of which has been published only in abstract form, found people who took Wegovy and Ozempic, also referred to as GLP-1 agonist drugs, were 30% more at risk of developing abdominal paralysis compared to those who did not. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), also known as GLP-1 agonists, are a class of medications used to treat Type 2 diabetes and obesity., , Read More